

<b>General information about company</b>	
Scrip code*	541096
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE365Y01019
Name of company	BHARAT PARENTERALS LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	12-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	05-05-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	12-05-2025 16:00
End date and time of board meeting	12-05-2025 17:30
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	08-08-2024
Indicate Company website link for updated RPT policy of the Company	<a href="https://www.bplindia.in/policies.html">https://www.bplindia.in/policies.html</a>
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
	Not Applicable

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-01-2025	01-04-2024	
Date of end of reporting period		31-03-2025	31-03-2025	
Whether results are audited or unaudited		Audited	Audited	
Nature of report standalone or consolidated		Standalone	Standalone	
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>			
<b>1</b>	<b>Income</b>			
	Revenue from operations	8028	30413	
	Other income	226	1456	
	<b>Total income</b>	<b>8254</b>	<b>31869</b>	
<b>2</b>	<b>Expenses</b>			
(a)	Cost of materials consumed	5135	17834	
(b)	Purchases of stock-in-trade	0	113	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	354	1014	
(d)	Employee benefit expense	567	2138	
(e)	Finance costs	148	479	
(f)	Depreciation, depletion and amortisation expense	182	705	
<b>(g)</b>	<b>Other Expenses</b>			
1	Other Expenses	1512	5954	
	<b>Total other expenses</b>	<b>1512</b>	<b>5954</b>	
	<b>Total expenses</b>	<b>7898</b>	<b>28237</b>	
<b>3</b>	<b>Total profit before exceptional items and tax</b>	<b>356</b>	<b>3632</b>	
4	Exceptional items	0	0	
<b>5</b>	<b>Total profit before tax</b>	<b>356</b>	<b>3632</b>	
<b>6</b>	<b>Tax expense</b>			
7	Current tax	115	1008	
8	Deferred tax	-5	-72	
<b>9</b>	<b>Total tax expenses</b>	<b>110</b>	<b>936</b>	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-18	-51	
<b>11</b>	<b>Net Profit Loss for the period from continuing operations</b>	<b>228</b>	<b>2645</b>	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
<b>14</b>	<b>Net profit (loss) from discontinued operation after tax</b>	<b>0</b>	<b>0</b>	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
<b>16</b>	<b>Total profit (loss) for period</b>	<b>228</b>	<b>2645</b>	
17	<a href="#">Other comprehensive income net of taxes</a>	21	6	
<b>18</b>	<b>Total Comprehensive Income for the period</b>	<b>249</b>	<b>2651</b>	
<b>19</b>	<b>Total profit or loss, attributable to</b>			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
<b>20</b>	<b>Total Comprehensive income for the period attributable to</b>			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
<b>21</b>	<b>Details of equity share capital</b>			
	Paid-up equity share capital	689	689	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve	0		
<b>23</b>	<b>Earnings per share</b>			
<b>i</b>	<b>Earnings per equity share for continuing operations</b>			
	Basic earnings (loss) per share from continuing operations	3.48	40.36	
	Diluted earnings (loss) per share from continuing operations	3.48	40.36	
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
<b>iii</b>	<b>Earnings per equity share (for continuing and discontinued operations)</b>			
	Basic earnings (loss) per share from continuing and discontinued operations	3.48	40.36	
	Diluted earnings (loss) per share from continuing and discontinued operations	3.48	40.36	
24	Debt equity ratio			Textual Information( 1)

25	Debt service coverage ratio			Textual Information( 2)
26	Interest service coverage ratio			Textual Information( 3)
<b>27</b>	<b>Disclosure of notes on financial results</b>	<b>Textual Information(4)</b>		

**Text Block**

Textual Information(4)

1.The above standalone results, standalone statement of Assets and Liabilities and standalone statement of Cash Flow have been audited by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors of the company.

2.The Company has only one segment of activity, namely "Pharmaceuticals."

3.Figures for the quarter ended 31st March, 2025 and corresponding quarter ended in the previous year as reported in these financial results are the balancing figures in respect of the full financial year and the published year-to-date figures up to the end of third quarter of the relevant financial year. Also the figures up to the end of third quarter had only been reviewed and not subject to audit.

4.Additional information for the investor are provided hereunder: Rs. In Lakhs

Particulars	Quarter Ended 31.03.2025	Year Ended 31.12.2024	Year Ended 31.03.2024	Year Ended 31.03.2025	Year Ended 31.03.2024
EBITDA (In Figures) including other income	685	1,214	698	4,815	4,100
EBITDA (In Figures) excluding other income	459	835	374	3,360	3,295
EBITDA (including other income)/ Revenue from operation (In %)	8.54%	18.03%	10.63%	15.83%	15.89%
EBITDA (excluding other income)/ Revenue from operation (In %)	5.72%	12.40%	5.69%	11.05%	12.77%

5.The Board of directors has passed resolution on 5th June 2024 for Allotment of fresh fully paid up 7,04,781 Nos. of equity share ranking pari-passu with existing equity shares having face value of Rs. 10 each at issue price of Rs. 1356.40 per share (including security premium of Rs.1346.40 per equity share) to Non - Promoter & Non-QIP investors on preferential basis in compliance with Companies Act, 2013, SEBI ICDR regulations and other applicable provisions.

6. The Company has acquired 99,85,477 shares in its subsidiary Innoxel Biolifescience Private Ltd against the consideration of Rs 6,480.57 lakhs.

7. During the year, the company has acquired 100% stake in Varenym Healthcare Pvt Ltd by issuing it's 351,255 fully paid equity shares of face value of Rs. 10 each against 250,000 fully paid equity shares of face value of Rs. 10 each of Varenym Healthcare Pvt Ltd from its Shareholders. The Swap Ratio has been determined based on the Valuation Report from an Independent Registered Valuer.

8. During the year, the company has further acquired 40% stake in Varenym Biolifesciences Pvt Ltd by issuing it's 16,261 fully paid equity shares of face value of Rs. 10 each against 180,000 fully paid equity shares of face value of Rs. 10 each of Varenym Biolifesciences Pvt Ltd from its shareholder i.e., Varenym Healthcare Pvt Ltd. The Swap Ratio has been determined based on the Valuation Report from an Independent Registered Valuer.

9. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
<b>Assets</b>		
<b>1</b>	<b>Non-current assets</b>	
	Property, plant and equipment	4537
	Capital work-in-progress	500
	Investment property	81
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	<b>Non-current financial assets</b>	
	Non-current investments	16780
	Trade receivables, non-current	0
	Loans, non-current	6192
	Other non-current financial assets	67
	<b>Total non-current financial assets</b>	<b>23039</b>
	Deferred tax assets (net)	82
	Other non-current assets	102
	<b>Total non-current assets</b>	<b>28341</b>
<b>2</b>	<b>Current assets</b>	
	Inventories	4685
	<b>Current financial asset</b>	
	Current investments	0
	Trade receivables, current	16472
	Cash and cash equivalents	34
	Bank balance other than cash and cash equivalents	2744
	Loans, current	10
	Other current financial assets	507
	<b>Total current financial assets</b>	<b>19767</b>
	Current tax assets (net)	1
	Other current assets	2125
	<b>Total current assets</b>	<b>26578</b>
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	<b>Total assets</b>	<b>54919</b>
	<b>Total current assets</b>	<b>26578</b>
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	<b>Total assets</b>	<b>54919</b>
<b>Equity and liabilities</b>		
<b>1</b>	<b>Equity</b>	
	<b>Equity attributable to owners of parent</b>	
	Equity share capital	689
	Other equity	37993
	<b>Total equity attributable to owners of parent</b>	<b>38682</b>
	Non controlling interest	
	<b>Total equity</b>	<b>38682</b>
<b>2</b>	<b>Liabilities</b>	
	<b>Non-current liabilities</b>	
	<b>Non-current financial liabilities</b>	
	Borrowings, non-current	227
	<b>Trade Payables, non-current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	<b>Total Trade payable</b>	
	Other non-current financial liabilities	281
	<b>Total non-current financial liabilities</b>	<b>508</b>
	Provisions, non-current	266
	Deferred tax liabilities (net)	0

	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	<b>Total non-current liabilities</b>	774
	<b>Current liabilities</b>	
	<b>Current financial liabilities</b>	
	Borrowings, current	6248
	<b>Trade Payables, current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	623
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	5653
	<b>Total Trade payable</b>	6276
	Other current financial liabilities	2059
	<b>Total current financial liabilities</b>	14583
	Other current liabilities	829
	Provisions, current	26
	Current tax liabilities (Net)	25
	Deferred government grants, Current	0
	<b>Total current liabilities</b>	15463
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	<b>Total liabilities</b>	16237
	<b>Total equity and liabilities</b>	54919
	<b>Disclosure of notes on assets and liabilities</b>	<b>Textual Information(1)</b>

<b>Other Comprehensive Income</b>			
	Date of start of reporting period	01-01-2025	01-04-2024
	Date of end of reporting period	31-03-2025	31-03-2025
	Whether results are audited or unaudited	Audited	Audited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Remeasurement of Defined benefit plans	28.00	8.00
2	Income tax relating to Remeasurement of Defined benefit plans	-7.00	-2.00
	Total Amount of items that will not be reclassified to profit and loss	21.00	6.00
2	Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	21.00	6.00

<b>Cash flow statement, indirect</b>		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2024
	Date of end of reporting period	31-03-2025
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	3632
2	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	479
	Adjustments for decrease (increase) in inventories	758
	Adjustments for decrease (increase) in trade receivables, current	-2547
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-389
	Adjustments for decrease (increase) in other non-current assets	89
	Adjustments for other financial assets, non-current	21
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	1036
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-934
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	705
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	69
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	522
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	-22
	Adjustments for dividend income	0
	Adjustments for interest income	-649
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	97.64
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	62.91
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	<b>596.55</b>
	<b>Net cash flows from (used in) operations</b>	<b>4228.55</b>
	Dividends received	0
	Interest paid	0
	Interest received	475
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	63
	<b>Net cash flows from (used in) operating activities</b>	<b>4766.55</b>
3	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	45
	Purchase of property, plant and equipment	-2030
	Proceeds from sales of investment property	0
	Purchase of investment property	-6481
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0

	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	1400
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	475
	Income taxes paid (refund)	1007
	Other inflows (outflows) of cash	2346
	<b>Net cash flows from (used in) investing activities</b>	<b>8970</b>
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	9290
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	-1689
	Repayments of borrowings	139
	Payments of lease liabilities	0
	Dividends paid	58
	Interest paid	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-479
	<b>Net cash flows from (used in) financing activities</b>	<b>6925</b>
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>20661.55</b>
<b>5</b>	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	-121
	<b>Net increase (decrease) in cash and cash equivalents</b>	<b>20540.55</b>
	Cash and cash equivalents cash flow statement at beginning of period	143
	<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>20683.55</b>

**Format for Disclosure of Related Party Transactions (applicable only for h**

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Val trans durir repc pe
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary							
1	BHARAT PARENTERALS LIMITED	AAACB8636N	Innoxel Lifesciences Private Limited	AAFCI8584D	Subsidiary	Advance		5000	Approved			8
2	BHARAT PARENTERALS LIMITED	AAACB8636N	Innoxel Lifesciences Private Limited	AAFCI8584D	Subsidiary	Investment		5000	Approved			
3	BHARAT PARENTERALS LIMITED	AAACB8636N	Innoxel Lifesciences Private Limited	AAFCI8584D	Subsidiary	Sale of goods or services		7500	Approved			
4	BHARAT PARENTERALS LIMITED	AAACB8636N	Varenyam Healthcare Private Limited	AAFCV5417L	Subsidiary	Sale of goods or services		7500	Approved			96
5	BHARAT PARENTERALS LIMITED	AAACB8636N	Varenyam Healthcare Private Limited	AAFCV5417L	Subsidiary	Advance		5000	Approved			
6	BHARAT PARENTERALS LIMITED	AAACB8636N	Varenyam Healthcare Private Limited	AAFCV5417L	Subsidiary	Purchase of goods or services		7500	Approved			21
7	BHARAT PARENTERALS LIMITED	AAACB8636N	Varenyam Healthcare Private Limited	AAFCV5417L	Subsidiary	Sale of goods or services		7500	Approved			
8	BHARAT PARENTERALS LIMITED	AAACB8636N	Bharat Desai	ABWPD8288Q	Managing Director	Remuneration		500	Approved			71
9	BHARAT PARENTERALS LIMITED	AAACB8636N	Hemang Shah	ADPPS0431D	Director	Remuneration		500	Approved			14
10	BHARAT PARENTERALS LIMITED	AAACB8636N	Bhahim B Desai	BACPD4375E	Relatives of Director	Remuneration		75	Approved			37
11	BHARAT PARENTERALS LIMITED	AAACB8636N	Nikita Desai	FRWPS8149J	Relatives of Director	Remuneration		45	Approved			20
12	BHARAT PARENTERALS LIMITED	AAACB8636N	Himaben b. Desai	ACUPD6891J	Relatives of Director	Remuneration		200	Approved			86
13	BHARAT PARENTERALS LIMITED	AAACB8636N	Varenyam Biolifesciences Private Limited	AAICV8323J	Subsidiary	Advance			Approved			82
14	BHARAT PARENTERALS LIMITED	AAACB8636N	Varenyam Biolifesciences Private Limited	AAICV8323J	Subsidiary	Investment			Approved			24
15	BHARAT PARENTERALS LIMITED	AAACB8636N	Varenyam Healthcare Private Limited	AAFCV5417L	Subsidiary	Investment			Approved			519
16	BHARAT PARENTERALS LIMITED	AAACB8636N	Innoxel Lifesciences Private Limited	AAFCI8584D	Subsidiary	Interest received			Approved			12
17	BHARAT PARENTERALS LIMITED	AAACB8636N	Varenyam Biolifesciences Private Limited	AAICV8323J	Subsidiary	Interest received			Approved			77
Total value of transaction during the reporting period												702

**Details of Impact of Audit Qualification**

Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	M/s. Shah Mehta and Bakshi	Yes	31-07-2025

<b>Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)</b>	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	28-05-2024
Amount Raised	956
Report filed for Quarter ended	31-03-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Not applicable
Comments of the auditors, if any	Not applicable

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Capital Adequacy for Expansion of Business	Not Applicable	71.69	0	0	0	Refer to Note no.1
2	Investment in Subsidiary Company	Not Applicable	764.77	0	648	0	Refer to Note no.2
3	Funds for General Corporate Purposes of the Company	Not Applicable	119.49	0	119.5	0	Completely utilised for the purpose

**Signatory Details**

Name of signatory	Bharatkumar Desai
Designation of person	Managing Director
Place	Vadodara
Date	12-05-2025

